Dr. Luikenhuis's presentation is Oct. 27 at 11 a.m. ET at the Harvard Medical School. In her session, "Skin in the Game," she will discuss PPD Dermatology's approach to evaluating the safety and efficacy of novel compounds originally intended for systemic, nondermatological therapies to investigate their potential as topical treatments for dermatological conditions. The presentation will elaborate on the unique advantages of accessing PPD's compound partnering resources to drive clinical development of a lead compound through Phase II.
"There are few novel dermatologic products currently being developed to treat skin diseases effectively," said Dr. Luikenhuis. "This conference provides an excellent forum to exchange information on cutting-edge research and development programs with leading biopharmaceutical companies in the Boston area."
The conference joins prominent leaders from top academic institutions who have been influential in establishing the strong Boston biotech community with executives from several of the area's most aspiring biopharmaceutical companies, as well as leaders from the venture capital community and equity markets.
PPD formed PPD Dermatology earlier this year, following its acquisition of Magen BioSciences. The acquisition expanded PPD's compound partnering program into dermatology. PPD gained a pipeline of compounds through Magen's exclusive license to develop and commercialize preclinical compounds discovered by Eli Lilly & Co. for dermatologic therapeutics initially in the indications of psoriasis, atopic dermatitis and acne.
Source
PPD
Our Recommendations:
• Buy Cipro Online No Prescription
• Buy Gleevec Online Without Prescription
• Purchase Medrol Online
• Purchase Aciphex
Nenhum comentário:
Postar um comentário